Level of Fatigue in Women Receiving Dose-Dense Versus Standard Chemotherapy for Breast Cancer: A Pilot Study
Purpose/Objectives: To determine whether women receiving dosedense chemotherapy for breast cancer experience different levels of fatigue than women receiving standard chemotherapy regimens for the disease.
Design: Quasi-experimental pilot study.
Setting: Private physicians' offices in California.
Sample: 15 women with stage I, II, or III breast cancer receiving dose-dense or standard chemotherapy. The average female participant was 48 years old (X = 48.3), was married (80%), and had a college degree (73%).
Methods: The revised Piper Fatigue Scale was completed by patients at three different times: pretreatment, three days after their cycle 1 chemotherapy dose, and three days after their cycle 2 chemotherapy dose. Patients returned completed surveys by mail.
Main Research Variables: Fatigue levels associated with chemotherapy.
Findings: Pretreatment total fatigue scores were not significantly different in the dose-dense and standard chemotherapy groups. Total fatigue scores were significantly higher in the dose-dense group at the cycle 1 and 2 time points. Fatigue scores were significantly higher in women who had undergone a mastectomy, were working, were HER2 positive, and had a tumor size larger than 2 cm.
Conclusions: Dose-dense chemotherapy resulted in significantly greater fatigue.
Implications for Nursing: Nurses should educate women receiving dose-dense chemotherapy as part of informed consent and assist them in preparing and planning for fatigue. Information about which patients are more likely to experience significant fatigue allows nurses to judge the frequency with which they need to assess and manage fatigue to improve patient outcomes.
Jump to a section
References
American Cancer Society. (2006). Cancer facts and figures 2006. Retrieved July 25, 2006, from http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf
Berger, A.M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25, 51-62.
Berger, A.M., & Higginbotham, P. (2000). Correlates of fatigue during and following adjuvant breast cancer chemotherapy: A pilot study. Oncology Nursing Forum, 27, 1443-1448.
Bottomley, A., Therasse, P., Piccart, M., Efficace, F., Coens, C., Gotay, C., et al. (2005). Health-related quality of life in survivors of locally advanced breast cancer: An international randomized controlled phase III trial. Lancet Oncology, 6, 287-294.
Bower, J.E., Ganz, P.A., Desmond, K.A., Rowland, J.H., Meyerowitz, B.E., & Belin, T.R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18, 743-753.
Cella, D., Lai, J.S., Chang, C.H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94, 528-538.
Citron, M.L., Berry, D.A., Cirrincione, C., Hudis, C., Winer, E.P., Gradishar, W.J., et al. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of nodes positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B trial 9741. Journal of Clinical Oncology, 21, 1431-1439.
Curt, G.A., Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist, 5, 353-360.
de Jong, N., Candel, M.J., Schouten, H.C., Abu-Saad, H.H., & Courtens, A.M. (2004). Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy. Annals of Oncology, 15, 896-905.
de Jong, N., Courtens, A.M., Abu-Saad, H.H., & Schouten, H.C. (2002). Fatigue in patients with breast cancer receiving adjuvant chemotherapy: A review of the literature. Cancer Nursing, 25, 283-297.
Fairclough, D.L., Fetting, J.H., Cella, D., Wonson, W., & Moinpour, C.M. (1999). Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Quality of Life Research, 8, 723-731.
Green, D., Nail, L.M., Fieler, V.K., Dudgeon, D., & Jones, L.S. (1994). A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer. Cancer Practice, 2, 57-62.
Hann, D.M., Garovoy, N., Finkelstein, B., Jacobsen, P.B., Azzarello, L.M., & Fields, K.K. (1999). Fatigue and quality of life in breast cancer patients undergoing autologous stem cell transplantation: A longitudinal comparative study. Journal of Pain and Symptom Management, 17, 311-319.
Hudis, C., & Norton, L. (2004). Evolving models in chemotherapy for breast cancer. Diseases of the Breast Updates, 7(4), 1-15.
Hwang, S.S., Chang, V.T., Rue, M., & Kasimis, B. (2003). Multidimensional independent predictors of cancer-related fatigue. Journal of Pain and Symptom Management, 26, 604-614.
Jacobsen, P.B., Hann, D.M., Azzarello, L.M., Horton, J., Balducci, L, & Lyman, G.H. (1999). Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates. Journal of Pain and Symptom Management, 18, 233-242.
Kubista, E., Glaspy, J., Holmes, F.A., Green, M.D., Hackett, J., Neumann, T., et al. (2003). Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clinical Breast Cancer, 3, 391-398.
Longman, A.J., Braden, C.J., & Mishel, M.H. (1997). Pattern of association over time of side-effects burden, self-help, and self-care in women with breast cancer. Oncology Nursing Forum, 24, 1555-1560.
Mast, M.E. (1998). Correlates of fatigue in survivors of breast cancer. Cancer Nursing, 21, 136-142.
Mock, V., Dow, K.H., Meares, C.J., Grimm, P.M., Dienemann, J.A., Haisfield-Wolfe, M.E., et al. (1997). Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncology Nursing Forum, 24, 991-1000.
National Comprehensive Cancer Network. (2003). Cancer-related fatigue: Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 1, 308-331.
Piper, B.F., Dibble, S.L., Dodd, M.J., Weiss, M.C., Slaughter, R.E., & Paul, S.M. (1998). The revised Piper Fatigue Scale: Psychometric evaluation in women with breast cancer. Oncology Nursing Forum, 25, 677-684.
Piper, B.F., Lindsey, A.M., & Dodd, M.J. (1987). Fatigue mechanisms in cancer patients: Developing nursing theory. Oncology Nursing Forum, 14, 17-23.
Richardson, A., Ream, E., & Wilson-Barnett, J. (1998). Fatigue in patients receiving chemotherapy: Patterns of change. Cancer Nursing, 21, 17-30.
Schwartz, A.H. (2002). Validity of cancer-related fatigue instruments. Pharmacotherapy, 22, 1433-1441.
Stone, P., Richards, M., & Hardy, J. (1998). Fatigue in patients with cancer. European Journal of Cancer, 34, 1670-1676.
Tchen, N., Juffs, H.G., Downie, F.P., Yi, Q.L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.
von Minckwitz, G., Raab, G., Caputo, A., Schutte, M., Hilfrich, J., Blohmer, J., et al. (2005). Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. Journal of Clinical Oncology, 23, 2676-2685.
Woo, B., Dibble, S.L., Piper, B.F., Keating, S.B., & Weiss, M.C. (1998). Differences in fatigue by treatment methods in women with breast cancer. Oncology Nursing Forum, 25, 915-920.
Wu, H., & McSweeney, M. (2001). Measurement of fatigue in people with cancer. Oncology Nursing Forum, 28, 1371-1384.